Orion Biotech Opportunities Corp.
ORIAW
NASDAQ Capital Market0.00
USD
-0.01
- -
CIK
0001847416
Return %
Stock
S&P500
1Y
-99.43
26.84
3Y
-99.88
77.03
5Y
-99.88
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Zuie-Chin Huang
- Sector
- Financial Services
- Industry
- Shell Companies
- Address
- CIK
- 0001847416
- Similar Companies
- Business
- Orion Biotech Opportunities Corp. (ORIAW) operates as a blank check company whose principal business activity is to effect a merger, share exchange, capital stock exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. The company focuses exclusively on targets in the biotechnology and life sciences sectors, particularly healthcare companies in North America, Europe, and Asia that offer potential for transformational change through novel therapies or technologies; it currently has no significant operations or revenues. Incorporated in 2021 and headquartered in New York, New York, Orion Biotech Opportunities Corp. completed a $200 million initial public offering in May 2021, sponsored by affiliates of MSD Partners and Panacea Venture. In March 2023, the company announced the redemption of its public shares and its decision not to consummate an initial business combination, resulting in its liquidation as a special purpose acquisition company without completing a merger or acquisition.